Connect Biopharma's rademikibart COPD readout faces model coin-flip on treatment failure rate
The Phase 2 Seabreeze STAT trial has slipped its primary completion date twice, and AppliedXL puts the endpoint-met odds at 49.4% for a placebo-controlled study of a mechanism untested in acute COPD exacerbation.
Executive Summary
- Connect Biopharma expects topline data in the second half of 2026 from Seabreeze STAT COPD, a randomized, placebo-controlled Phase 2 trial testing rademikibart as an add-on to standard of care in acute COPD exacerbation, with treatment failure rate as the primary endpoint. No biologic is currently approved for this indication.
- The trial's primary completion date moved from April 1, 2026 to June 1, 2026, disclosed on April 27, 2026, a two-month slip that has already passed without the trial exiting Recruiting status as of the June 12, 2026 registry update.
- AppliedXL puts the endpoint-met probability at 49.4%, with a wide confidence band (39.4% to 59.4%) and a LOW confidence label, meaning the model itself flags this as a low-conviction call heading into the readout.
- No direct comparator has reported results in acute COPD exacerbation specifically; Dupilumab, Stapokibart, and Lunsekimig all target IL-13 in COPD but in chronic maintenance settings at later phases, leaving rademikibart without a same-design precedent to benchmark against.
- The dossier does not specify what magnitude of treatment failure reduction the company or FDA would consider meaningful, nor any historical placebo failure rate in this exact population, leaving the bar for a genuinely positive readout undefined.
The catalyst
Connect Biopharma Holdings Limited (Connect Biopharm LLC) expects topline data in the second half of 2026 from the Phase 2 Seabreeze STAT COPD trial (NCT06940154), which tests rademikibart added to standard of care against placebo in patients experiencing an acute COPD exacerbation NCT06940154+1Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)NCT06940154Press ReleaseMar 31, 2025. The primary endpoint is treatment failure rate, tracked alongside seven secondary measures including change in lung function (FEV1) and a validated exacerbation symptom scale (EXACT-PRO score) NCT06940154Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)NCT06940154. CEO Barry Quart, Pharm.D., framed the program's ambition in March 2025: "We believe rademikibart has the potential to fundamentally alter the treatment paradigm for millions of asthma and COPD patients who experience acute exacerbations every year" Press ReleasePress ReleaseMar 31, 2025.
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What's at stake
No biologic therapy is currently approved for acute COPD exacerbation, a gap the company has repeatedly cited as its opening Press ReleasePress ReleaseMar 31, 2025. The trial enrolls 160 patients, randomized between an active arm and a placebo arm, testing whether blocking IL-13 signaling through the IL-4Ralpha receptor can reduce treatment failure in the acute setting rather than the chronic maintenance setting where this mechanism class has been studied more extensively NCT06940154Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)NCT06940154.
Timing risk
The trial's primary completion date moved from April 1, 2026 to June 1, 2026, a change disclosed on April 27, 2026. That date has now passed, and the trial remained in Recruiting status as of the most recent registry update on June 12, 2026, rather than Active, not recruiting or Completed. AppliedXL's own readout-timing model puts the point estimate for data at August 5, 2026, with a range extending to November 5, 2026, and assigns only a 51% probability that a readout lands within 90 days and 68% within 180 days. The company has issued the same H1 or H2 2026 guidance across at least seven separate disclosures since March 2025, without narrowing the window.
The model read
AppliedXL's endpoint-met probability sits at 49.4%, with a wide band from 39.4% to 59.4% and a LOW confidence label attached [AXL-MODEL]. That reflects a mixed driver picture: enrollment per arm and subcutaneous route of administration both push the read higher, while the mechanism-indication fit score and scientific plausibility score for this specific pairing pull it lower [AXL-MODEL]. The model's separate regulatory-approval head reads 66.2%, but that figure describes a hypothetical post-endpoint pathway, not the trial's own decision-grade evidence, since the study is explicitly non-registrational [NCT06940154, AXL-MODEL].
Competitive frame
The closest direct comparators by mechanism, target, and indication are Dupilumab, Stapokibart, and Lunsekimig, all targeting IL-13 in COPD. None of these three tests an acute-exacerbation add-on design; they are chronic maintenance trials measuring annualized exacerbation rates over multi-year horizons. That leaves rademikibart without a same-design precedent in this exact clinical setting, and the acute-exacerbation biologic category itself remains unprecedented at the regulatory level.
Information value
This readout, if it lands within the stated window, comes from a Phase 2, randomized, placebo-controlled, 160-patient trial: adequately powered for a signal but too small and non-registrational to be decision-grade for approval NCT06940154Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)NCT06940154. The real information value sits in whether the treatment-failure signal holds up alongside the FEV1 and EXACT-PRO secondary measures, and whether the company commits to a larger, registrational design following this readout NCT06940154Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)NCT06940154.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.